<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904485</url>
  </required_header>
  <id_info>
    <org_study_id>2019N020KY</org_study_id>
    <nct_id>NCT03904485</nct_id>
  </id_info>
  <brief_title>Assessment of Myocardial Injury in Simultaneous Pancreas and Kidney Transplantation</brief_title>
  <acronym>AMI-SPK</acronym>
  <official_title>Assessment of Myocardial Injury in Recipients of Simultaneous Pancreas and Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin First Central Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic cardiomyopathy( DCM) is a major complication of diabetes and is a common
      cardiovascular complication independent of coronary artery disease and hypertension．Trial to
      assess of myocardial injury in recipients of simultaneous pancreas and kidney transplantation
      by nuclear magnetic T２ mapping technology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Evaluate the changes of myocardial injury before and after SPK by cardiac magnetic
           resonance imaging (CMR),

        2. Evaluate the value of SPK in the repair of myocardial injury by comparing with the
           single renal transplant in recipients with diabetic nephropathy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of myocardial injury</measure>
    <time_frame>1year</time_frame>
    <description>Assessment of myocardial injury between two groups</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Simultaneous Pancreas-kidney Transplantation</condition>
  <condition>Diabetic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>SPKT</arm_group_label>
    <description>patients with end-stage diabetic nephropathy got simultaneous pancreas-kidney transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT</arm_group_label>
    <description>patients with end-stage diabetic nephropathy got single kidney transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>cardiac magnetic resonance(CMR) T2 mapping</intervention_name>
    <description>T2 value before transplant，3 month and 6month after transplant</description>
    <arm_group_label>RT</arm_group_label>
    <arm_group_label>SPKT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 25 patients with SPK who met the inclusion criteria and 25 patients with simple
        kidney transplantation for diabetic end-stage nephropathy were included by matching the
        onset time, gender, age, BMI and blood pressure of diabetes
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients with type 2 diabetes were treated with SPK; 2.No definite history of
             cardiovascular diseases (such as congenital heart disease, coronary heart disease,
             cardiomyopathy or valvular heart disease, etc.); 3. Preoperative hemodialysis 4. No
             history of heart failure

        Exclusion Criteria:

          1. Contraindications in cardiac magnetic resonance imaging；2.poorly controlled
             hypertension；3.CMR examination revealed marked hypertrophy of the left ventricular
             myocardium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tianjin First central hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004 Jul;52(1):141-6.</citation>
    <PMID>15236377</PMID>
  </reference>
  <reference>
    <citation>Ding H, Fernandez-de-Manuel L, Schär M, Schuleri KH, Halperin H, He L, Zviman MM, Beinart R, Herzka DA. Three-dimensional whole-heart T2 mapping at 3T. Magn Reson Med. 2015 Sep;74(3):803-16. doi: 10.1002/mrm.25458. Epub 2014 Sep 19.</citation>
    <PMID>25242141</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin First Central Hospital</investigator_affiliation>
    <investigator_full_name>Yingxin FU.MD</investigator_full_name>
    <investigator_title>Director of kidney transplantation center</investigator_title>
  </responsible_party>
  <keyword>SPK ,DCM,CMR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Diabetic Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Study data including numbers, clinical data, and corresponding CMR results, were shared every three months</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

